Literature DB >> 7960020

Clinical studies on the sites of production and clearance of circulating adrenomedullin in human subjects.

T Nishikimi1, K Kitamura, Y Saito, K Shimada, T Ishimitsu, M Takamiya, K Kangawa, H Matsuo, T Eto, T Omae.   

Abstract

Adrenomedullin is a novel hypotensive peptide, newly discovered in pheochromocytoma. Because immunoreactive adrenomedullin is present in human plasma, adrenomedullin may play a role in regulating blood pressure. A recent report showed that human adrenomedullin mRNA is expressed not only in pheochromocytoma but also in the normal adrenal medulla, kidney, lung, and ventricle. However, whether or not these organs actually release adrenomedullin into the circulation remains unknown. To investigate the sites of production and degradation of adrenomedullin in human subjects, we obtained blood samples from various sites and measured immunoreactive adrenomedullin concentrations. In study 1, blood samples were obtained from the infrarenal inferior vena cava, suprarenal inferior vena cava, superior vena cava, right atrium, right ventricle, pulmonary artery, pulmonary capillary, left ventricle, and aorta during cardiac catheterization in 15 patients with ischemic heart disease (67 +/- 10 years). In study 2, blood samples were taken from the infrarenal inferior vena cava, suprarenal inferior vena cava, right and left renal veins, and left adrenal vein in 5 hypertensive patients (42 +/- 14 years) suspected of having renovascular hypertension. In study 3, peripheral venous blood samples were obtained in 2 patients (males, 45 and 36 years old) with pheochromocytoma at rest and during hypertensive attacks. Plasma adrenomedullin concentrations were measured by a newly developed radioimmunoassay. In study 1, there were no significant differences in plasma adrenomedullin concentrations in various sites of the right-side circulation. There was no step-up of plasma adrenomedullin levels in the coronary sinus. However, the plasma concentration of adrenomedullin in aorta was slightly but significantly lower than in pulmonary artery.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7960020     DOI: 10.1161/01.hyp.24.5.600

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  20 in total

1.  Hypertension in patients with pheochromocytoma.

Authors:  N N Hanna; D E Kenady
Journal:  Curr Hypertens Rep       Date:  1999-12       Impact factor: 5.369

2.  Increased pericardial fluid concentrations of the mature form of adrenomedullin in patients with cardiac remodelling.

Authors:  K Tambara; M Fujita; N Nagaya; S Miyamoto; A Iwakura; K Doi; G Sakaguchi; K Nishimura; K Kangawa; M Komeda
Journal:  Heart       Date:  2002-03       Impact factor: 5.994

3.  Adrenomedullin and nitric oxide in children with detrusor instability.

Authors:  Ayşe Balat; Kemal Sarica; Mustafa Cekmen; Muhittin Yürekli; Faruk Yağci; Ahmet Erbağci
Journal:  Pediatr Nephrol       Date:  2003-04-08       Impact factor: 3.714

4.  Adrenomedullin suppresses fMLP-induced upregulation of CD11b of human neutrophils.

Authors:  Y Saito; C Nakagawa; H Uchida; F Sasaki; H Sakakibara
Journal:  Inflammation       Date:  2001-06       Impact factor: 4.092

Review 5.  Adrenomedullin. Implications for hypertension research.

Authors:  K Kitamura; K Kangawa; H Matsuo; T Eto
Journal:  Drugs       Date:  1995-04       Impact factor: 9.546

6.  Proadrenomedullin NH(2)-terminal 20 peptide, a new product of the adrenomedullin gene, inhibits norepinephrine overflow from nerve endings.

Authors:  T Shimosawa; Y Ito; K Ando; K Kitamura; K Kangawa; T Fujita
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

7.  Increase in plasma adrenomedullin in patients with heart failure characterised by diastolic dysfunction.

Authors:  C M Yu; B M Cheung; R Leung; Q Wang; W H Lai; C P Lau
Journal:  Heart       Date:  2001-08       Impact factor: 5.994

8.  Plasma concentrations of adrenomedullin correlate with the extent of pulmonary hypertension in patients with mitral stenosis.

Authors:  T Nishikimi; S Nagata; T Sasaki; S Tomimoto; H Matsuoka; S Takishita; K Kitamura; A Miyata; H Matsuo; K Kangawa
Journal:  Heart       Date:  1997-10       Impact factor: 5.994

9.  Two molecular forms of adrenomedullin in congenital heart disease.

Authors:  K Watanabe; T Nishikimi; M Takamuro; K Yasuda; Y Ishikawa; S Tanabe; O Yamada; N Nagaya; H Matsuoka; K Kangawa; S Echigo
Journal:  Pediatr Cardiol       Date:  2003-09-04       Impact factor: 1.655

10.  Midregional pro-adrenomedullin in addition to b-type natriuretic peptides in the risk stratification of patients with acute dyspnea: an observational study.

Authors:  Mihael Potocki; Tobias Breidthardt; Tobias Reichlin; Nils G Morgenthaler; Andreas Bergmann; Markus Noveanu; Nora Schaub; Heiko Uthoff; Heike Freidank; Lorenz Buser; Roland Bingisser; Michael Christ; Alexandre Mebazaa; Christian Mueller
Journal:  Crit Care       Date:  2009-07-23       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.